Core Points - Pingtan Development and Haixia Innovation have completed their suspension review and will resume trading on November 21, 2025 [1][2] - Eddy Precision and Hangcai Co. plan to repurchase shares [3] - Wenfeng Co.'s deputy general manager has been placed under investigation [4] - Kesi Co. has undergone a change in its actual controller [6][7] - Major events include the completion of restructuring investments by *ST Lian Shi and acquisitions by Jun Ting Hotel and Lek Electric [8][9] Group 1: Resumption of Trading - Pingtan Development's stock will resume trading on November 21, 2025, after confirming no significant changes in its operations or undisclosed major matters [1] - Haixia Innovation's stock will also resume trading on November 21, 2025, with similar confirmations regarding its operational status [2] Group 2: Share Repurchase Plans - Eddy Precision plans to repurchase shares with a total amount between 100 million and 200 million yuan, at a price not exceeding 27 yuan per share [3] - Hangcai Co. intends to repurchase shares using excess funds, with a total amount between 50 million and 100 million yuan, at a price not exceeding 80 yuan per share [3] Group 3: Investigations and Changes in Management - Wenfeng Co.'s deputy general manager, Qin Guofen, is under investigation, but the company states this will not significantly impact its operations [4] - Kesi Co. has changed its actual controller from Zhou Jiuqing and Zhou Xuming to Zhou Xuming alone following the death of Zhou Jiuqing [6][7] Group 4: Major Events - *ST Lian Shi has received a total of 1.238 billion yuan in restructuring investments from all investors [8] - Jun Ting Hotel has agreed to acquire the remaining 21% stake in Junlan Management for 79.8 million yuan, making it a wholly-owned subsidiary [9] - Lek Electric plans to transfer 90% of its subsidiary's equity to Chuangyuan Resources, with a target valuation of 235 million yuan [9]

Core Viewpoint - The company, Maiwei Biotechnology, has received approval from the China Securities Regulatory Commission for its overseas listing plan, indicating a significant step towards expanding its capital base and market presence [1] Group 1: Company Announcement - Maiwei Biotechnology announced that it plans to issue up to 62.6646 million overseas listed ordinary shares [1] - The company intends to list these shares on the Hong Kong Stock Exchange [1]

Core Viewpoint - Maiwei Biotechnology has received approval from the China Securities Regulatory Commission for its overseas listing plan, indicating a significant step towards its expansion in international markets [1] Group 1 - The company plans to issue no more than 62.6646 million overseas listed ordinary shares (H shares) [1] - The shares will be listed on the Hong Kong Stock Exchange, which is a strategic move to enhance its market presence [1]

证券代码：688062 证券简称：迈威生物 公告编号：2025-067 迈威（上海）生物科技股份有限公司 关于发行境外上市外资股（H 股） 获得中国证监会备案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迈威（上海）生物科技股份有限公司（以下简称"公司"）于近日收到中 国证券监督管理委员会（以下简称"中国证监会"）出具的《关于迈威（上海） 生物科技股份有限公司境外发行上市备案通知书》（国合函〔2025〕2062 号） （以下简称"备案通知书"）。备案通知书主要内容如下： 一、公司拟发行不超过 62,664,600 股境外上市普通股并在香港联合交易所 上市。 二、自备案通知书出具之日起至本次境外发行上市结束前，公司如发生重 大事项，应根据境内企业境外发行上市有关规定，通过中国证监会备案管理信 息系统报告。 四、公司自备案通知书出具之日起 12 个月内未完成境外发行上市，拟继 续推进的，应当更新备案材料。 备案通知书仅对企业境外发行上市备案信息予以确认，不表明中国证监会 对公司证券的投资价值或者投资者的收益作出实质性 ...

Core Viewpoint - The company, Maiwei Biotechnology, has received a notification from the China Securities Regulatory Commission regarding its plan for overseas issuance and listing in Hong Kong [1] Group 1: Company Actions - The company plans to issue no more than 62,664,600 overseas listed ordinary shares [1] - The company is required to report any significant events to the China Securities Regulatory Commission through the designated management information system until the completion of the overseas issuance and listing [1] - Within 15 working days after the completion of the overseas issuance and listing, the company must report the issuance and listing status to the China Securities Regulatory Commission [1] Group 2: Regulatory Compliance - The company must strictly adhere to relevant domestic and foreign laws, regulations, and rules during the overseas issuance and listing process [1]

Core Viewpoint - The company has received a filing notice from the China Securities Regulatory Commission (CSRC) for the proposed issuance of up to 62,664,600 overseas listed common shares to be listed on the Hong Kong Stock Exchange, indicating a significant step towards international expansion [1] Group 1 - The company plans to issue a maximum of 62,664,600 shares [1] - The shares will be listed on the Hong Kong Stock Exchange [1] - The company must report any major events from the issuance notice until the end of the issuance [1] Group 2 - The completion of the issuance and listing is subject to approval from relevant Hong Kong authorities, introducing an element of uncertainty [1] - The company is required to report the situation within 15 working days after the completion of the issuance and listing [1]

格隆汇11月20日｜迈威生物公告，公司于近日收到中国证监会出具的《关于迈威(上海)生物科技股份有 限公司境外发行上市备案通知书》。公司拟发行不超过62,664,600股境外上市普通股并在香港联合交易 所上市。公司申请发行境外上市外资股(H股)并上市尚需取得香港证券及期货事务监察委员会和香港联 合交易所有限公司等相关政府机关、监管机构、证券交易所的批准、核准，该事项仍存在不确定性。 ...

迈威生物晚间公告，公司于近日收到中国证监会出具的《关于迈威（上海）生物科技股份有限公司境外 发行上市备案通知书》。根据备案通知书，公司拟发行不超过6266.46万股境外上市普通股并在香港联 合交易所上市。自备案通知书出具之日起至本次境外发行上市结束前，公司如发生重大事项，应根据境 内企业境外发行上市有关规定，通过中国证监会备案管理信息系统报告。公司完成境外发行上市后15个 工作日内，应通过中国证监会备案管理信息系统报告发行上市情况。 ...

Core Insights - Maiwei Biotech has received approval from the National Medical Products Administration (NMPA) for its IL-11 monoclonal antibody 9MW3811 to enter Phase II clinical trials for pathological scars, marking it as the first drug targeting this indication in clinical exploration [1] - The company has established an exclusive licensing agreement with CALICO Life Sciences, which includes an upfront payment of $25 million and potential milestone payments totaling up to $571 million, along with tiered royalties based on net sales [1][2] - Maiwei Biotech reported a significant revenue increase of 301.03% year-on-year, reaching 566 million yuan in the first three quarters of 2025, driven primarily by income from innovative product collaborations [2] Group 1: Clinical Development and Partnerships - The company has a comprehensive pipeline with 15 core products at various stages, including 11 innovative drugs and 4 biosimilars, focusing on oncology and age-related diseases [2] - The Phase II clinical trial for the anti-TMPRSS6 monoclonal antibody 9MW3011 has commenced, with the first patient dosed in the U.S., marking a significant milestone in its collaboration with DISC Medicine [3] - Maiwei Biotech has entered into a partnership with Qilu Pharmaceutical for long-acting white blood cell-boosting drugs, with a contract value of up to 500 million yuan, including a non-refundable upfront payment of 380 million yuan [4] Group 2: Financial Performance - The substantial increase in technical service revenue is attributed to the licensing agreements with CALICO, Qilu, and DISC, indicating the successful commercialization of innovative research [4] - The company’s revenue from technical services reached 407 million yuan, a year-on-year increase of 715.52%, while drug sales contributed 156 million yuan, reflecting a 72.10% increase [2] - Maiwei Biotech's ongoing clinical trials for its core pipeline products, including 9MW2821 and JS207, show promising efficacy signals in treating triple-negative breast cancer [5]

11月13日，有消息称国内一家生物制药企业解散肿瘤销售团队，信息指向迈威生物。对此，智通财经记 者致电迈威生物董秘办/证代公开电话，接电人员表示公司未解散肿瘤销售团队，但也未告知记者目前 肿瘤销售团队人员数量，仅表示公司有统计研发人员数量，并在财报中披露。此后，记者再次联系迈威 生物，公司表示不回应此事。（智通财经） ...